



## MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

October 5, 2022

- Clinical data on AgenT-797, allogeneic (allo) iNKTs, +/- anti-PD-1 in advanced solid tumors
- Clinical data of AgenT-797 in viral ARDS and refractory multiple myeloma
- New therapeutic candidates: 1) MiNK-215, an allo-FAP-CAR-iNKT; 2) MiNK-413, allo-*armored*-BCMA-CAR-iNKT

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- [MiNK Therapeutics](https://minktherapeutics.com/), Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the acceptance of five abstracts for presentation at the Society for Immunotherapy of Cancer's (SITC) 37<sup>th</sup> Annual Meeting, to be held November 8 – 12<sup>th</sup>, 2022.

### Presentation Details:

**Abstract Title:** Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma

**Abstract number:** 647

**Presenting Author:** Dr. David Einstein

**Details:** Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

**Abstract Title:** Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (viral ARDS) secondary to SARS-CoV-2 (COVID-19)

**Abstract Number:** 649

**Presenting Author:** Dr. Terese Hammond

**Details:** Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

**Abstract Title:** Development of an allogeneic FAP-CAR-iNKT product to target tumor stroma and modulate the Tumor Microenvironment

**Abstract Number:** 358

**Presenting Author:** Xavier Michelet, PhD

**Details:** Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

**Abstract Title:** MiNK-413: a Next generation armored allogeneic BCMA-CAR-iNKT product

**Abstract Number:** 322

**Presenting Author:** Eleni Chantzoura, PhD

**Details:** Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

**Abstract Title:** agenT-797, a native allogeneic "off-the-shelf" invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment

**Abstract Number:** 372

**Presenting Author:** Sapana Kadel

**Details:** Poster Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET

### About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit <https://minktherapeutics.com/>.

### Contact

Kimberly Ha

KKH Advisors

917-291-5744

[kimberly.ha@kxhadvisors.com](mailto:kimberly.ha@kxhadvisors.com)



Source: MiNK Therapeutics